Comparative Pharmacology
Head-to-head clinical analysis: BETAPACE versus DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BETAPACE versus DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE.
BETAPACE vs DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Class III antiarrhythmic agent; prolongs cardiac action potential duration and refractory period by blocking potassium channels, primarily IKr.
Dorzolamide is a carbonic anhydrase inhibitor that reduces aqueous humor secretion by inhibiting carbonic anhydrase in the ciliary processes. Timolol is a non-selective beta-adrenergic receptor antagonist that reduces aqueous humor production by blocking beta-2 adrenergic receptors in the ciliary epithelium.
Oral: 80 mg twice daily; may increase up to 160 mg twice daily as needed.
One drop of the fixed combination (dorzolamide 22.26 mg/mL, timolol 6.83 mg/mL) in the affected eye(s) every 12 hours.
None Documented
None Documented
12 hours (10-20 hours) in patients with normal renal function; prolonged in renal impairment, requiring dose adjustment
Dorzolamide: ~4 months but accumulates in RBCs; terminal half-life ~4-5 months due to binding to carbonic anhydrase. Timolol: ~4-6 hours.
Renal: >90% unchanged drug (sotalol) in urine; biliary/fecal: <10%
Dorzolamide: primarily renal (approx. 80% unchanged), with minor biliary/fecal elimination. Timolol: renal (15-20% unchanged) and extensive hepatic metabolism with fecal excretion.
Category C
Category A/B
Beta-Blocker
Beta-Blocker